Contemporary studies about vaccination against human papillomavirus (original) (raw)
Related papers
Mediterranean Journal of Infection Microbes and Antimicrobials, 2020
Introduction: Human papilloma virus (HPV) is the most common viral infection of the urogenital system in men and women. Despite the high protection rate of HPV vaccine, vaccination rates in our country remain below the optimal level. The aim of this study is to determine the attitudes of parents working in the health sector towards having their children vaccinated against HPV. Materials and Methods: The universe of the research was formed by all employees of İstanbul Koşuyolu High Specialization Training and Research Hospital. The questionnaire consisting of 21 questions was applied to a total of 151 people by face to face method. Results: One hundred and fifty one employees working in Koşuyolu High Specialization Training and Research Hospital were included in the study. Of the employees, 68.9% of whom were women, 18 (11.9%) stated that they had HPV vaccine. Only two employees responded positively to the question of whether their children had HPV vaccine; 27 of them (17.9%) were found to be thinking of having their children vaccinated against HPV in the future. When employees were asked why they did not want ttheir children to be vaccinated against HPV, most (33.8%) stated that the vaccine was expensive, while 17.2% thought that the vaccine was not protective. Conclusion: Diseases caused by HPV, especially cervical cancer, can be prevented by vaccination. It is thought that this disease can be prevented by vaccination as well as sexual health education and the use of condoms. However, there may be a negative attitude towards vaccination among healthcare professionals. In terms of public health, it is thought that increasing education on this issue will positively affect both employees and the public.
Vaccination for Human Papillomavirus: an historic and bibliometric study
Human Vaccines & Immunotherapeutics, 2020
A systematic literature review was conducted to describe in a historical perspective the evolution of studies concerning HPV vaccination. The search identified 794 articles of which 568 were included. The first article was published in 2001, and the maximum annual number of publications was reached in 2014. The average number of authors per paper was 8.8. Papers originated from 49 different countries, with the USA accounted for the maximum number of publications (n = 217). Efficacy (46.5%) and safety (31.0%) were the most prevalent objectives. Clinical trials constituted the largest group of methods (37.9%). Chronological trends did not reveal any lasting curve-crossings, indicating that the priority topics have remained the same. The geographical origin of these studies raises questions about the transposability of the results to populations where HPV vaccination has been studied only a little. This study could help guide future research to less-studied research objectives, particularly for vaccines.
Vaccines for human papillomavirus infection: A critical analysis
Indian Journal of Dermatology, Venereology and Leprology, 2009
This article takes a critical look at the pros and cons of human papillomavirus (HPV) vaccines. There is enough evidence to suggest that the prophylactic vaccines are efÞ cacious in preventing various benign and malignant conditions (including cervical cancers) caused by HPV. Even though the vaccine is costly, hypothetical analysis has shown that HPV vaccination will be cost effective in the long run. Therapeutic HPV vaccines used to treat established disease are still undergoing evaluation in clinical studies, and results seem to be encouraging. Although several countries have started mandatory vaccination programs with the prophylactic HPV vaccines, conservatives have voiced concerns regarding the moral impact of such vaccination programs.
Human papilloma virus vaccination: impact and recommendations across the world
Therapeutic Advances in Vaccines, 2014
Human papilloma virus (HPV) vaccination has been implemented in several countries for about the past 7 years, mainly in the adolescent female population, with varying coverage results. Although the impact of immunization on cervical and other HPV-related cancers will be evident in the next decades, a marked decrease of prevalent HPV infections, precancerous lesions and genital warts is already dramatic in the vaccinated cohorts, and also in their sexual partners, thus providing clear evidence of the effectiveness of HPV vaccination, including a herd-protection effect. Today, recommendations and implementation of universal HPV vaccination for adolescent girls are a public-health priority in all countries of the world. Countries with limited resources are presently involved in demonstration projects and, in some cases, have launched national programmes with the help of international agencies and alliances. Extension of immunization offer to young women and to adolescent male subjects ...
Human papillomavirus vaccine: A boon or curse
Human Vaccines & Immunotherapeutics, 2014
C ervical cancer is the second most common cancer among women worldwide, with about 493,000 new cases diagnosed annually. Of 274,000 deaths due to cervical cancer each year, more than 80% occur in developing countries, and this proportion is expected to increase to 90% by 2020. Up to 70% of sexually active women will become infected with human papilloma virus (HPV) during their lifetime. Even though screening reduces the risk of cervical cancer, it does not prevent HPV infection or development of precancerous lesions which need careful follow-up and often need excision. It was observed in a study, pre-adolescent vaccination alone reduced cancer incidence by 44% and was more effective than screening alone. A combined approach of pre-adolescent vaccination and screening of adult women was more effective than either alone. The high probability of acquiring HPV infection once, one has become sexually active raises the question of whether the vaccine will be effective if given to girls who have already been infected with HPV type 16 or 18. In April 2010, The Indian parliament's Standing Committee on Health, began probing the use of HPV vaccines in 2 states after the reported deaths of 7 girls, and concluded that "safety and rights of children were highly compromised and violated." Though the question of immunization of older girls and women deserves attention, from a public health perspective, the first priority in resource-poor settings would be to vaccinate young adolescent girls.
Vaccination against human papilloma virus in the light of quaternary prevention
Revista Brasileira de Medicina de Família e Comunidade
Apesar dos benefícios demonstrados, a questão da vacinação massiva contra o HPV ainda está sujeita a intensas discussões e controvérsias. A proteção contra o câncer ainda não está comprovada e precisa de mais tempo para ser precisa sobre a quantificação da redução do câncer do colo do útero. A análise da relevância da vacina contra o HPV é muito complexa devido a vários níveis sobrepostos que devem ser considerados. Os autores analisam muitas das questões éticas, sociológicas, econômicas, políticas e, finalmente, científicas envolvidas nesta análise. A confiança da população nas vacinas foi afetada devido às práticas duvidosas de muitas empresas farmacêuticas. Diante dessa manipulação de informações em escala global, clínicos gerais, família e comunidade se organizaram para lutar contra a incerteza. A prevenção quaternária, conceito apoiado pela Organização Mundial de Médicos de Família, defende a aplicação de procedimentos eticamente aceitáveis nos cuidados médicos. Este artigo de ...
Vaccination to prevent human papillomavirus infections: From promise to practice
PLOS Medicine, 2017
• A large proportion of the disease burden related to infection with human papillomavirus (HPV), the most common sexually transmitted infection, can be prevented through vaccination. • There is inequity in access to HPV vaccines, and populations with the largest burden of HPV-related diseases have the least access to the vaccines. • Affordability and sustainable financing of HPV vaccination are barriers to introduction in low-and middle-income countries because of the relatively high cost of the vaccine and its delivery to a nontraditional target population.
Human papilloma virus vaccine – more than a vaccine
Current Opinion in Obstetrics and Gynecology, 2007
Purpose of review In February 2006, this journal summarized the scientific and psychosocial data generated about the first generation of prophylactic human papilloma virus vaccines. Since then, the world has held its breath, as the first vaccine to be aimed at the prevention of cancer has made its global debut. We look at this debut in the context of recent findings. Recent findings Many countries have embarked on vaccination programmes to target prevention and media attention has continued unabated. Studies show promising results regarding vaccine acceptance and cost-effectiveness. Who we vaccinate and the quality of campaign materials used now have the potential to alter the very effectiveness of these vaccines as primary preventive tools. With the licensing of Gardasil a new era has started for patients and health professionals alike. Far from a passive new development foisted upon us, it promises to play a pivotal role: to optimize patient information and to advocate strategies we wish health policy makers to achieve. Summary We aim to summarize how updated information, since this debut, can add to our consultations and help give us a collective voice to address the rising healthcare disparities involved.
2024
The background of the study Uganda is overflowing with many women of reproductive age at risk of developing cervical cancer. Getting immunized with the HPV vaccine could be the only hope to avert this risk. WHO greatly recommends HPV vaccination to combat the spread of the HPV vaccine. However, despite availing the HPV vaccine in health facilities, its uptake remains stunted. The objective of the study The objective of the study was to determine the factors associated with the uptake of Human Papillomavirus vaccination among female adolescents attending Kajjansi Health Center IV in Wakiso district. Study methods The study was of a cross-sectional descriptive design that utilized quantitative methods of data collection. This enabled the researcher to collect data from a large number of respondents (100 respondents) within a short period. Results A total of 100 questionnaires were collected. The score rates of knowledge were 63%, and those of attitude towards its effectiveness were 46% and uptake rates were 54%. The main factors influencing knowledge were age, attitude towards its effectiveness, and the source of information. Altitude was affected by socioeconomic status, and the uptake was mainly affected by the side effects experienced. Conclusions It was evident that most participants had information about HPV vaccination, although it was insufficient for them to complete the series. The side effects of the vaccine, inadequate health worker recommendation, inadequate knowledge about the safety of the vaccine, and absence of school-based vaccination programs were observed to influence its uptake. Recommendations Mass sensitization of the public should go on to enhance a complete understanding of the need to start and complete the series of HPV vaccinations. Any program aimed at creating mass awareness about HPV vaccination at any level should be boosted by the people in charge.
Journal of preventive medicine and hygiene, 2009
The Human Papilloma Virus (HPV) is one of the most important oncogenic viruses for humans. Researches on its epidemiology, pathogenic mechanisms and preventive tools had an acceleration since preventive HPV vaccines started their way towards approval by regulatory authorities. An impressive number of articles have been published in international journals in the last years, and the same can be said about presentations and posters at congresses, meetings and symposia. One of the most important yearly events where new research data are usually anticipated, is the International Papillomavirus Conference, whose 25 edition was held in Malmo, Sweden, on May 8-14, 2009. We summarise here a few particularly interesting selected studies presented at the Conference regarding Papillomavrus preventative vaccines.